Publisher Correction: Podcast: Influenza-Associated Complications and the Impact of Vaccination on Public Health
(Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - February 16, 2024 Category: Infectious Diseases Source Type: research
Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands —a Holistic Approach
ConclusionOur analysis reflects the high economic burden of MenB-related IMD in the Netherlands. Sequelae costs represent a high proportion of the total costs. Societal costs were dependent on the applied approach (FCA or HCA).Graphical Plain Language Summary (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - February 16, 2024 Category: Infectious Diseases Source Type: research
Publisher Correction: Podcast: Influenza-Associated Complications and the Impact of Vaccination on Public Health
(Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - February 16, 2024 Category: Infectious Diseases Source Type: research
A Systematic Literature Review on Risk Factors for and Timing of Clostridioides difficile Infection in the United States
ConclusionThis SLR uses recent evidence to define the most important factors associated with CDI, confirming those that are well established and highlighting new ones that could help to identify patient populations at high risk.Graphical Abstract (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - February 13, 2024 Category: Infectious Diseases Source Type: research
Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016 –2019
ConclusionsWhen accounting for under-ascertainment, estimated RSV-attributable hospitalizations were higher than those reported based on standard-of-care RSV-specific codes in all age groups but particularly among older children and older adults. Like other respiratory viruses, RSV contributes to both respiratory and cardiovascular complications. Efficacious RSV vaccines could have a high public health impact in these age and risk groups. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - February 6, 2024 Category: Infectious Diseases Source Type: research
A Systematic Literature Review on Risk Factors for and Timing of Clostridioides difficile Infection in the United States
ConclusionThis SLR uses recent evidence to define the most important factors associated with CDI, confirming those that are well established and highlighting new ones that could help to identify patient populations at high risk.Graphical Abstract (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - February 1, 2024 Category: Infectious Diseases Source Type: research
Epidemiology of Pertussis and Pertussis-Related Complications in Adults: A German Claims Data Analysis
ConclusionThis study shows that adults with certain UCs have an increased risk for pertussis and are more likely to have complications. These results provide further evidence that pertussis is a relevant and impactful infectious disease in adults with and without certain UC, indicating that these patients need to be considered when developing vaccination recommendations to avoid pertussis and its associated complications.A graphical abstract is available with this article.Graphical Abstract (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 31, 2024 Category: Infectious Diseases Source Type: research
First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study
ConclusionsSingle-dose KB demonstrated favorable safety and tolerability in healthy subjects at the dose level of 0.005 –0.48 mg/kg. KB exhibited a non-linear pharmacokinetic profile with a half-life of about 1.61–4.24 h, which mainly distributed in plasma.Trial RegistrationClinicalTrials.gov identifier, NCT02219971. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 30, 2024 Category: Infectious Diseases Source Type: research
Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial
ConclusionThe study demonstrated that a significantly lower proportion of patients with mild-to-moderate COVID-19 treated with BAM or BAM + (ETE or sotrovimab) experienced a PHVL at day 7.Trial RegistrationClinicalTrials.gov identifier, NCT04634409. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 30, 2024 Category: Infectious Diseases Source Type: research
Association Between Risk of Clostridium difficile Infection and Duration of Proton Pump Inhibitor or H2-Receptor Antagonist Use in Hospitalized Patients
ConclusionsThe optimal cutoff duration for PPI and H2RA use was about 2 weeks. It is necessary to be cautious regarding the risk of CDI in patients taking PPIs or H2RAs for longer than 2 weeks. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 30, 2024 Category: Infectious Diseases Source Type: research
First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study
ConclusionsSingle-dose KB demonstrated favorable safety and tolerability in healthy subjects at the dose level of 0.005 –0.48 mg/kg. KB exhibited a non-linear pharmacokinetic profile with a half-life of about 1.61–4.24 h, which mainly distributed in plasma.Trial RegistrationClinicalTrials.gov identifier, NCT02219971. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 30, 2024 Category: Infectious Diseases Source Type: research
Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial
ConclusionThe study demonstrated that a significantly lower proportion of patients with mild-to-moderate COVID-19 treated with BAM or BAM + (ETE or sotrovimab) experienced a PHVL at day 7.Trial RegistrationClinicalTrials.gov identifier, NCT04634409. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 30, 2024 Category: Infectious Diseases Source Type: research
Association Between Risk of Clostridium difficile Infection and Duration of Proton Pump Inhibitor or H2-Receptor Antagonist Use in Hospitalized Patients
ConclusionsThe optimal cutoff duration for PPI and H2RA use was about 2 weeks. It is necessary to be cautious regarding the risk of CDI in patients taking PPIs or H2RAs for longer than 2 weeks. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - January 30, 2024 Category: Infectious Diseases Source Type: research
